Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A L de Goede

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Annales Pharmaceutiques Francaises|December 16, 2014
Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infectionA L de Goede, A G Vulto, A D M E Osterhaus, et al.
Annales Pharmaceutiques Francaises|December 22, 2014
Understanding HIV infection for the design of a therapeutic vaccine. Part II: Vaccination strategies for HIVA L de Goede, A G Vulto, A D M E Osterhaus, et al.
Intensive Care Medicine|September 28, 2011
Stability of sildenafil (Revatio®) dilutions in dextrose 5%A F Y Al Hadithy, A L de Goede, M Eckhardt, et al.
International Journal of Pharmaceutics|May 15, 2012
Development and validation of a paediatric oral formulation of clonidine hydrochlorideA L de Goede, R R Boedhram, M Eckhardt, et al.
Tissue Antigens|February 8, 2012
Sequence evolution and escape from specific immune pressure of an HIV-1 Rev epitope with extensive sequence similarity to human nucleolar protein 6S D Allard, A L de Goede, B De Keersmaecker, et al.
Clinical Pharmacology and Therapeutics|February 7, 2008
Pharmacogenetics: from bench to byteJ J Swen, I Wilting, A L de Goede, et al.
Cancer Immunology, Immunotherapy : CII|July 21, 2023
Good manufacturing practice production of CD34<sup>+</sup> progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemiaP K J D de Jonge, P M M van Hauten, L D Janssen, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Annales Pharmaceutiques Francaises|December 16, 2014
Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infectionA L de Goede, A G Vulto, A D M E Osterhaus, et al.
Annales Pharmaceutiques Francaises|December 22, 2014
Understanding HIV infection for the design of a therapeutic vaccine. Part II: Vaccination strategies for HIVA L de Goede, A G Vulto, A D M E Osterhaus, et al.
Intensive Care Medicine|September 28, 2011
Stability of sildenafil (Revatio®) dilutions in dextrose 5%A F Y Al Hadithy, A L de Goede, M Eckhardt, et al.
International Journal of Pharmaceutics|May 15, 2012
Development and validation of a paediatric oral formulation of clonidine hydrochlorideA L de Goede, R R Boedhram, M Eckhardt, et al.
Tissue Antigens|February 8, 2012
Sequence evolution and escape from specific immune pressure of an HIV-1 Rev epitope with extensive sequence similarity to human nucleolar protein 6S D Allard, A L de Goede, B De Keersmaecker, et al.
Clinical Pharmacology and Therapeutics|February 7, 2008
Pharmacogenetics: from bench to byteJ J Swen, I Wilting, A L de Goede, et al.
Cancer Immunology, Immunotherapy : CII|July 21, 2023
Good manufacturing practice production of CD34<sup>+</sup> progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemiaP K J D de Jonge, P M M van Hauten, L D Janssen, et al.
Pageof 1